JPS5949239B2 - Simple purification method for high-purity protamine - Google Patents
Simple purification method for high-purity protamineInfo
- Publication number
- JPS5949239B2 JPS5949239B2 JP53074132A JP7413278A JPS5949239B2 JP S5949239 B2 JPS5949239 B2 JP S5949239B2 JP 53074132 A JP53074132 A JP 53074132A JP 7413278 A JP7413278 A JP 7413278A JP S5949239 B2 JPS5949239 B2 JP S5949239B2
- Authority
- JP
- Japan
- Prior art keywords
- protamine
- purification
- purification method
- purity
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 108010007568 Protamines Proteins 0.000 title claims description 35
- 102000007327 Protamines Human genes 0.000 title claims description 35
- 229940048914 protamine Drugs 0.000 title claims description 29
- 238000000746 purification Methods 0.000 title claims description 11
- 238000000034 method Methods 0.000 title description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 8
- 239000011707 mineral Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 239000007864 aqueous solution Substances 0.000 claims description 5
- 239000003463 adsorbent Substances 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 3
- 239000003960 organic solvent Substances 0.000 claims description 3
- 238000000926 separation method Methods 0.000 claims description 3
- 241000251468 Actinopterygii Species 0.000 claims description 2
- 238000000605 extraction Methods 0.000 claims description 2
- 230000001376 precipitating effect Effects 0.000 claims description 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 229950008679 protamine sulfate Drugs 0.000 description 6
- 108010016290 deoxyribonucleoprotamine Proteins 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical class [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229940121657 clinical drug Drugs 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 241000252203 Clupea harengus Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 235000019514 herring Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000001226 reprecipitation Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 102000016261 Long-Acting Insulin Human genes 0.000 description 1
- 108010092217 Long-Acting Insulin Proteins 0.000 description 1
- 229940100066 Long-acting insulin Drugs 0.000 description 1
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 1
- 101710093543 Probable non-specific lipid-transfer protein Proteins 0.000 description 1
- 241000277331 Salmonidae Species 0.000 description 1
- 241000269821 Scombridae Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 230000002668 anti-heparin effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000019688 fish Nutrition 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- VRWKTAYJTKRVCU-UHFFFAOYSA-N iron(6+);hexacyanide Chemical compound [Fe+6].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] VRWKTAYJTKRVCU-UHFFFAOYSA-N 0.000 description 1
- 235000020640 mackerel Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000005341 metaphosphate group Chemical group 0.000 description 1
- -1 nucleic acid copper salt Chemical class 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- CLSUSRZJUQMOHH-UHFFFAOYSA-L platinum dichloride Chemical compound Cl[Pt]Cl CLSUSRZJUQMOHH-UHFFFAOYSA-L 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019983 sodium metaphosphate Nutrition 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- CMPGARWFYBADJI-UHFFFAOYSA-L tungstic acid Chemical compound O[W](O)(=O)=O CMPGARWFYBADJI-UHFFFAOYSA-L 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Description
【発明の詳細な説明】
本発明は、高純度プロタミンの簡易な精製方法に関する
ものである。DETAILED DESCRIPTION OF THE INVENTION The present invention relates to a simple method for purifying high purity protamine.
プロタミンはサケ、マス、ニシン、サバ等の精子核中に
デオキシリボ核酸と結合したヌクレオプロタミンとして
存在する比較的分子量の小さい、高アルギニン含量の強
塩基性タンパク質である。Protamine is a strong basic protein with a relatively small molecular weight and high arginine content that exists as nucleoprotamine bound to deoxyribonucleic acid in the sperm nuclei of salmon, trout, herring, mackerel, etc.
プロタミンは古くより、インシュリンとの複合体である
効力持続性インシュリン製剤や抗へパリン剤であるプロ
タミン注射液が臨床薬剤として使用されていると同時に
、生化学研究および生化学工業において分離、精製用薬
剤としても利用されているが、近時、ある種の酵素の安
定剤や抗性物質等の活性剤または助剤としても不可欠の
物質となりつゝある。従来、プロタミンの製造には、前
記魚の成熟白子の精子核より希鉱酸でプロタミンを抽出
するか、あるいは濃食塩水でヌクレオプロタミンを抽出
しそれからプロタミンを分離する方法がとられてきた。Protamine has long been used as a clinical drug in long-acting insulin preparations, which are complexes with insulin, and protamine injections, which are anti-heparin drugs. Although it is also used as a medicine, it has recently become an indispensable substance as a stabilizer for certain enzymes and as an activator or auxiliary agent for anti-inflammatory substances. Conventionally, protamine has been produced by extracting protamine from sperm nuclei of mature milt of the fish with dilute mineral acid, or by extracting nucleoprotamine with concentrated saline and then separating protamine.
しかし、これらの抽出物中には、プロタミン以外のタン
パク質、ペプチド類、アミノ酸類、核酸分解生成物、脂
質およびその分解生成物等が混在しているので、これか
ら適切な沈澱剤により単離したプロタミン鉱酸塩はかな
りの精製を要する。従来とられたプロタミンの精製法と
しては、(1)硫酸塩としてアルコールによる再沈澱の
反覆によるか、(2)ピクリン酸塩を経る処理で精製す
るか、(3)その他一般のタンパク沈澱剤(塩化白金、
タングステン酸、メタ燐酸、フェロシアン化水素酸、ス
ルホサルチル酸等)を利用するか、(4)イオン交換樹
脂により分離精製するのが一般的である、またヌクレオ
プロタミンとして抽出する場合は、(1)食塩濃度を下
げて再沈澱精製した後に希鉱酸でプロタミンを分離する
か、(2)ヌクレオプロタミンの塩類溶液からブロタミ
ンを塩析して分離精製するか、(3)硫酸銅もしくは塩
化銅で核酸銅塩として除去してプロタミン鉱酸塩を得る
等の諸方法が行われている。いずれにしても、これら従
来の精製法は操作が煩雑であるか、または高価な幅資材
を必要とするかして、大量生産には不適当であるのみか
、臨床薬剤用としては精製も不充分であり、純度の向上
を望めばブロタミンの収量を著しく減するという犠牲が
伴い、経済的に著しく不利である。However, since these extracts contain proteins other than protamine, peptides, amino acids, nucleic acid degradation products, lipids, and their degradation products, protamine isolated using an appropriate precipitant can be used. Mineral salts require considerable purification. Conventional purification methods for protamine include (1) repeated reprecipitation with alcohol as sulfate, (2) purification through treatment with picrate, or (3) other general protein precipitating agents ( platinum chloride,
(tungstic acid, metaphosphoric acid, ferrocyanic acid, sulfosalicylic acid, etc.) or (4) separation and purification using ion exchange resin. In addition, when extracting as nucleoprotamine, (1) salt concentration (2) Separate and purify brotamine by salting out from a salt solution of nucleoprotamine after reprecipitation purification by lowering the nucleoprotamine, or (3) Separate and purify the nucleic acid copper salt with copper sulfate or copper chloride. Various methods have been used to obtain protamine mineral salts by removing them as protamine mineral salts. In any case, these conventional purification methods are either unsuitable for mass production due to complicated operations or require expensive materials, or are unsuitable for purification for clinical drug use. However, if the desired purity is desired, the yield of brotamine will be significantly reduced, which is economically disadvantageous.
本発明の特徴は、プロタミンを含む白子より常法により
抽出分離して、前記不純物の混在するプロタミン鉱酸塩
を酸性の希薄水溶液中で吸着剤により、処理した後、必
要最少限量の有機溶剤で分別沈澱させることにより、臨
床薬剤としても充分に適応しうる高純度プロタミンを極
めて簡易に精製できることである。The feature of the present invention is that the protamine mineral salt containing protamine is extracted and separated from the milt containing protamine by a conventional method, and the impurity-containing protamine mineral salt is treated with an adsorbent in an acidic dilute aqueous solution. By performing fractional precipitation, it is possible to extremely easily purify high-purity protamine, which can be sufficiently applied as a clinical drug.
プロタミン以外のタンパク質とその分解生成物、核酸分
解生成物、脂質とその分解生成物等の不純物の相対量は
、原料白子、抽出条件、分離条件等により必ずしも画一
的ではなく、そのために、それぞれの不純物を除去する
原理に基いて、それぞれに目標を定めて、最適の除去精
製処理を施すことは実際上困難であり、それ故に最大公
約数的な条件の下で複数の操作の巧妙な組合せを必要と
する。The relative amounts of impurities such as proteins other than protamine and their decomposition products, nucleic acid decomposition products, lipids and their decomposition products, etc. are not necessarily uniform depending on the raw material Milt, extraction conditions, separation conditions, etc. Based on the principle of removing impurities, it is practically difficult to set targets for each impurity and perform optimal removal and purification treatment. Requires.
プロタミン鉱酸塩の酸性希薄水溶液中では、上記の不純
物とプロタミンとの化学結合士物理的付着はほとんど切
れるか、または離れた状態で溶解していること、および
プロタミン以外のものは吸着剤に著しい親和性があると
いう新知見を得て、高純度プロタミンを極めて簡易に精
製できる本発明を確立したのである。In an acidic dilute aqueous solution of protamine mineral salt, the chemical bonds and physical bonds between the above impurities and protamine are almost completely broken or dissolved in a separated state, and substances other than protamine are significantly attached to the adsorbent. Based on the new knowledge that there is an affinity for protamine, they established the present invention, which allows extremely simple purification of high-purity protamine.
もちろん吸着されない性質のものであつて、当然溶液中
に残存するために、沈澱操作に使用する有機溶剤の使用
量は、必要最少限量であることが重要である。Of course, it is of a non-adsorbable nature and naturally remains in the solution, so it is important that the amount of organic solvent used in the precipitation operation is the minimum necessary amount.
プロタミン水溶液の濃度は希薄であるほど好ましいが、
1〜10%内で自由に選択できる。酸性度は強いほど不
純物の溶解性は良く、通常は声3以下が望ましい。一般
の吸着剤(活性炭、活性アルミナ、シリカゲル、ベント
ナイト、酸性白土、ケイソウ土、骨炭等)はいずれも使
用することができ、主とする目的により適当に選択しう
る。使用量は何れも1〜10q6程度でよい。温度条件
は熱時、冷時いずれでもよく、処理時間は長時間ほど好
結果が得られる。有機溶剤もアルコール類、アセトン等
何れでもよく、使用量は当容以下が望ましい。以下、実
施例、参考例をあげる。The more dilute the concentration of the protamine aqueous solution, the better.
It can be freely selected within the range of 1 to 10%. The stronger the acidity, the better the solubility of impurities, and it is usually desirable that the acidity be 3 or less. Any general adsorbent (activated carbon, activated alumina, silica gel, bentonite, acid clay, diatomaceous earth, bone charcoal, etc.) can be used and can be appropriately selected depending on the main purpose. The amount used may be about 1 to 10q6. The temperature conditions may be hot or cold, and the longer the treatment time, the better the results. The organic solvent may be any alcohol, acetone, etc., and the amount used is preferably at most the equivalent volume. Examples and reference examples are given below.
参考例
ニシンの成熟白子25kgに0.5N塩酸601を加え
、常温で液の循環下に5時間抽出する。Reference Example 0.5N hydrochloric acid 601 was added to 25 kg of mature herring milt, and the mixture was extracted at room temperature for 5 hours while circulating the liquid.
分離した抽出液をアンモニア水でPl{3〜4に調整し
、これに6009のメタ燐酸ナトリウムの水溶液を攪拌
しつX添加して一夜放置する。上澄液を傾瀉してアメ状
のプロタミンメタ燐酸塩1.9k9を41の2モル硫酸
アンモニウムに加温溶解して一夜放置する。下層の油状
プロタミン硫酸塩をアルコールで脱水固化、乾燥して1
.0kgの硫酸プロタミンの白色粉末を得る。実施例
参考例で作製した硫酸プロタミン1k9を201の水に
加温溶解し、希硫酸でず1.5に調整する。The separated extract was adjusted to Pl{3 to 4 with aqueous ammonia, and an aqueous solution of sodium metaphosphate 6009 was added thereto with stirring and left overnight. The supernatant liquid was decanted, and candy-like protamine metaphosphate 1.9k9 was dissolved in 41 2M ammonium sulfate under heating and left overnight. The lower layer of oily protamine sulfate is dehydrated and solidified with alcohol, dried and
.. 0 kg of protamine sulfate white powder is obtained. Example: Protamine sulfate 1k9 prepared in the reference example was dissolved in 201 of water by heating, and adjusted to 1.5 with dilute sulfuric acid.
50gの活性炭を加えて1時間攪拌後、淵別する。After adding 50 g of activated carbon and stirring for 1 hour, the mixture was separated.
無色透明な硫酸プロタミン水溶液に攪拌下511のメタ
ノールを加え、一夜放置する。上澄液を傾瀉、アメ状プ
ロタミン硫酸塩を5!のメタノールで脱水固化し乾燥す
る。純白色の高純度硫酸プロタミンの結晶体8509が
得られる。モル%は全アミノ酸のモル数に対する各アミ
ノ酸のモル百分率を示す。511 methanol is added to a colorless and transparent aqueous protamine sulfate solution while stirring, and the mixture is left overnight. Decant the supernatant liquid and add 5 drops of candy-like protamine sulfate! Dehydrate and solidify with methanol. A pure white crystalline product 8509 of high purity protamine sulfate is obtained. Mol% indicates the mole percentage of each amino acid relative to the number of moles of all amino acids.
B紫外吸収B ultraviolet absorption
Claims (1)
プロタミン鉱酸塩の酸性希薄水溶液を吸着剤で処理した
後に、必要最少限量の有機溶剤で分別沈澱させることを
特徴とする高級度プロタミンの精製法。1 Purification of high-grade protamine characterized by treating an acidic dilute aqueous solution of protamine mineral salt obtained by extraction and separation from fish milt containing protamine with an adsorbent, and then precipitating it fractionally with the minimum necessary amount of an organic solvent. Law.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP53074132A JPS5949239B2 (en) | 1978-06-21 | 1978-06-21 | Simple purification method for high-purity protamine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP53074132A JPS5949239B2 (en) | 1978-06-21 | 1978-06-21 | Simple purification method for high-purity protamine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS552612A JPS552612A (en) | 1980-01-10 |
| JPS5949239B2 true JPS5949239B2 (en) | 1984-12-01 |
Family
ID=13538350
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP53074132A Expired JPS5949239B2 (en) | 1978-06-21 | 1978-06-21 | Simple purification method for high-purity protamine |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS5949239B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103509098A (en) * | 2012-06-20 | 2014-01-15 | 徐州万邦金桥制药有限公司 | Purification technology of protamine |
-
1978
- 1978-06-21 JP JP53074132A patent/JPS5949239B2/en not_active Expired
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103509098A (en) * | 2012-06-20 | 2014-01-15 | 徐州万邦金桥制药有限公司 | Purification technology of protamine |
| CN103509098B (en) * | 2012-06-20 | 2016-03-30 | 徐州万邦金桥制药有限公司 | The purifying process of protamine |
Also Published As
| Publication number | Publication date |
|---|---|
| JPS552612A (en) | 1980-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US3719655A (en) | Process for the crystallization of the ammonium and alkali metal salts in insulin | |
| NL8501105A (en) | PROCESS FOR THE PURIFICATION OF INSULIN. | |
| Abdel-Meguid et al. | Crystallization of a ribonuclease-resistant fragment of Escherichia coli 5 S ribosomal RNA and its complex with protein L25 | |
| US4661606A (en) | Extraction of amino acids from aqueous mixtures and quaternary ammonium salt intermediates produced therein | |
| JP4388698B2 (en) | Methods for recovering and purifying recombinant proteins from cells | |
| JPS5949239B2 (en) | Simple purification method for high-purity protamine | |
| JPH0151997B2 (en) | ||
| RU1838406C (en) | Method of preparing of biologically active components | |
| EP3054008A1 (en) | Method for purifying double-stranded ribonucleic acid | |
| Traub et al. | Interaction in vitro of the neurofilament triplet proteins from porcine spinal cord with natural RNA and DNA | |
| US3875138A (en) | Process for recovering glucagon | |
| JPS5931519B2 (en) | Extraction, separation and purification method of high purity protamine | |
| SU1657491A1 (en) | Method of producing taurin | |
| CN102617727B (en) | Thymalfasin compound and novel preparation method thereof | |
| RU2067868C1 (en) | Method of preparing basic proteinase inhibitor from cattle organs | |
| JPS5931518B2 (en) | How to extract protamine | |
| US4886888A (en) | Extraction of amino an acid from aqueous mixtures thereof | |
| EP0564775A2 (en) | Process for pharmaceutical grade high purity iodeoxycholic acid preparation | |
| DE2154557C3 (en) | Process for the production of high-purity kallidinogenase (kallikrein) and a medicament containing the crystalline kallidinogenase obtained thereafter | |
| JPH05500205A (en) | Hemin purification method, new hemin derivatives and their production method | |
| JPS5829294B2 (en) | Method for purifying isoleucine from a mixture of leucine and isoleucine | |
| JPS5949238B2 (en) | How to separate protamine | |
| IE45013B1 (en) | Improvements in or relating to the preparation of insulin | |
| CA1043775A (en) | Process for recovering glucagon | |
| JPH0699477B2 (en) | Method for purifying protamine mineral acid salt |